Medically reviewed by Dr. Ehtesham Ghani, Internal Medicine & Bariatric Medicine (ASBP). Last reviewed June 2026.
If you started a weight-loss journey on compounded semaglutide a year or two ago, you have probably noticed the rules shifting under your feet. Headlines about FDA warning letters, pharmacies pulling products, and telehealth companies exiting the market have left a lot of patients confused and worried. So let’s clear it up honestly: is compounded semaglutide still safe and legal in 2026? The short answer is that it can be legal in specific situations, but the landscape has changed dramatically, and physician supervision matters more now than ever. For a fuller side-by-side comparison, see our pillar guide on compounded vs. brand semaglutide.
What changed with compounded semaglutide in 2025 and 2026?
During the nationwide semaglutide shortage, federal law allowed compounding pharmacies to prepare their own versions of the drug to help fill the gap. That window began to close in February 2025, when the FDA declared the semaglutide shortage officially resolved. Once a drug is off the shortage list, the broad legal exemption that permitted widespread compounding no longer applies. The FDA gave state-licensed 503A pharmacies until April 22, 2025, and larger 503B outsourcing facilities until May 22, 2025, to wind down mass compounding of semaglutide.
Through 2026, the FDA has continued to enforce these limits, issuing warning letters and signaling that large-scale and mass-marketed compounding of semaglutide is no longer permitted. Many large telehealth platforms stopped offering compounded semaglutide as a result. The rules are still evolving, so what was acceptable last year may not be acceptable today.
Is compounded semaglutide legal at all in 2026?
Yes, but in narrower circumstances than before. Under federal rules, a state-licensed 503A compounding pharmacy may still prepare a compounded medication for an individual patient when there is a valid prescription and a documented clinical reason that a commercially available, FDA-approved product will not work for that specific person. Examples can include a documented allergy or sensitivity to an inactive ingredient in the brand product, or a clinically necessary dose that is not commercially available.
What is no longer appropriate is compounding simply because it is cheaper or more convenient than the brand drug, or producing it at scale for the general public. Among the brand options, Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved to treat type 2 diabetes and is sometimes used off-label for weight loss under a physician’s care. Because regulations in this area continue to change, the safest approach is to work with a physician who keeps up with current rules rather than ordering from an online source making broad claims.
What are the safety risks of compounded versions?
Compounded medications are not reviewed or approved by the FDA the way brand drugs are. That does not automatically make a properly compounded prescription unsafe, but it does mean quality depends heavily on the pharmacy. The biggest concerns regulators have raised include incorrect dosing, unverified ingredient sources, the use of salt forms of semaglutide that were never studied in patients, and products sold without genuine medical oversight.
Like all semaglutide products, this medication carries a boxed warning, the FDA’s most serious warning, regarding a risk of thyroid C-cell tumors based on animal studies. It is contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Semaglutide can also cause side effects such as nausea, vomiting, and, less commonly, pancreatitis or gallbladder problems. This is exactly why semaglutide, compounded or brand, belongs in a supervised medical program rather than a self-directed online purchase.
How well does semaglutide actually work?
In the STEP clinical trials of FDA-approved semaglutide, participants lost on average around 15% of their body weight over roughly 68 weeks when the medication was combined with diet and exercise. Those results came from studies of the brand product under medical supervision, and individual results vary. Compounded products have not been studied in the same way, so trial numbers should not be assumed to transfer directly. Whatever form is prescribed, semaglutide works best as one part of a complete plan that includes nutrition, physical activity, and ongoing medical follow-up, not as a standalone shortcut.
How does ThinFast MD handle this safely?
At ThinFast MD, we have provided physician-supervised medical weight loss across Illinois since 1984, with offices in Hinsdale, Arlington Heights, Brookfield, and Rockford. Our medical director, Dr. Ehtesham Ghani, evaluates each patient individually and, where appropriate, may prescribe brand semaglutide (Wegovy, or Ozempic off-label for weight loss), tirzepatide (Zepbound, or Mounjaro off-label), or other medically supported options. When a compounded medication is clinically appropriate and legally permitted for a specific patient, it is prescribed and monitored within a structured program, never sold from a faceless website.
Because the regulations around compounding keep changing, the most reliable thing you can do is talk with a physician who follows the current rules and puts your safety first. To find out which option fits your health history and goals, call ThinFast MD at (708) 485-4050 to schedule a consultation.
This article is for educational purposes only and is not medical advice. Weight-loss results vary from person to person, and no specific outcome is guaranteed. Always consult a qualified healthcare provider before starting or changing any medication or treatment. In a medical emergency, call 911.
